AbbVie's Q2 Beat Hid a 14-Cent Cut: Skyrizi Is Still the Cash Machine Investors Need

Q2 beat, lower 2026 EPS, and the market's real concern

AbbVie delivered a strong second quarter, but a revised full-year EPS range kept investors from celebrating.

On one hand, investors got roughly $300 million above forecast on revenue, adjusted earnings of $3.65 per share versus a $3.60 per share consensus, and solid execution across the core business. On the other, management changed its 2026 outlook to $13.87 to $14.07 per share, which includes a $0.14 per share dilutive impact from Apogee. That is the tension in the quarter: operating performance looked healthy, but the acquisition lowered the near-term EPS bar.

A useful way to read the result is to separate reported EPS optics from underlying operating momentum. AbbVie still produced a strong revenue quarter, and the core business remains the main source of cash while the company builds the next leg of growth.

Skyrizi and Rinvoq are still carrying the growth story

The main bullish point is straightforward: AbbVie's strongest portfolios are still expanding.

Skyrizi remains the centerpiece

Skyrizi generated $5.505 billion in second-quarter net revenues and remains the core growth engine. It is still doing the kind of work investors want from a flagship asset: leading immunology growth and continuing to win share in mature indications.

Rinvoq is becoming a more meaningful second pillar

Rinvoq contributed $2.525 billion in quarterly net revenues. Alongside Skyrizi, it helps show that AbbVie's immunology franchise is more than a one-drug story. The planned Apogee acquisition also fits that strategy, with assets aimed at expanding the immunology pipeline in dermatology and respiratory disease.

Neuroscience added support, but the portfolio still leans heavily on immunology

The neuroscience portfolio grew 20.3% on a reported basis, or 19.8% operationally, helped by Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta. Humira still contributed $756 million, a much smaller number than in earlier years but still part of the legacy revenue base.

One caution is important: the quarter's 22.9% adjusted EPS growth was aided by a smaller acquired-IPR&D and milestones expense at $0.17 per share versus $0.42 a year ago, which accounted for 37% of the increase. That helps explain why the EPS beat alone was not enough to change the market's focus.

What would keep the bullish case intact

The constructive view does not depend on one quarter. It depends on whether the core cash engine keeps supporting the transition.

Key signposts

• Skyrizi needs to keep compounding. The important test is whether strong market share gains in psoriasis and IBD continue to show up quarter over quarter.
• Apogee needs to justify the earnings impact. The company has said the deal is expected close in the third quarter of 2026. If the acquisition later shows up as meaningful immunology depth rather than just lower EPS, the 14-cent hit will look more like investment than leakage.
• The broader business needs to stay constructive. Management highlighted promising data readouts expected in the second half of 2026, which could matter for sentiment if the results support the pipeline narrative.

What would weaken the thesis

The case gets harder if competitive pressure in psoriasis increases, if the Apogee acquisition creates more dilution or timing issues than expected, or if growth becomes less broad-based than it was in Q2.

Why the stock still traded the guidance cut more heavily than the beat

Even after a strong quarter, AbbVie shares fell more than 4% in premarket trading after management set a $13.87 to $14.07 full-year adjusted EPS range. That reaction shows what investors cared about most: not the quarter itself, but how the Apogee deal changes the ownership math for 2026.

The bullish case is still reasonable because the underlying outlook did not collapse. Management indicated that $0.14 of Apogee dilution more than absorbed $0.10 of operating upside, which suggests the core business was still moving in the right direction before the deal impact was applied.

The bearish case is also understandable. Investors are increasingly focused on how long acquisition-led bridge building can support the story if the core portfolios eventually slow. Apogee may improve the immunology bench, but it also raises the expectation that AbbVie can keep earning its premium through better execution, not just smarter buying.

For now, the main question is simple: does Apogee become future platform strength, or mostly near-term earnings drag? If the former, this quarter can look like a temporary stumble. If the latter, the market may keep valuing AbbVie more cautiously.